Elizabeth Mily

Chief Executive Officer

---

Elizabeth A. Mily is a healthcare and financial industry veteran with more than 30 years of experience spanning biopharma, life sciences, and global healthcare investing. Most recently, she served as Executive Vice President, Strategy & Business Development at Bristol Myers Squibb, where she led the company’s external innovation strategy and oversaw business development, strategic partnerships, alliance management, mergers and acquisitions, and the company’s equity investing portfolio.

Prior to BMS, Elizabeth was a senior member of the Global Healthcare Group at Barclays, where she led the Life Sciences investment banking business across biopharma, life science tools, and diagnostics. She previously served as Senior Vice President of Corporate Strategy and Development at Thermo Fisher Scientific, and spent 16 years at Goldman Sachs, where she was a Managing Director in the Healthcare Investment Banking group.

Elizabeth holds an M.S. in Foreign Service from Georgetown University and a B.A. in German Literature and European History from The Ohio State University. She was a Fulbright Scholar to the Universities of Cologne and Hamburg and a Congress-Bundestag Scholar in Bonn. She currently serves on the Board of Directors of Solventum Corporation (NYSE: SOLV), including membership on the Audit and Quality, Science & Technology Committees, and is a director of Ampersand Biomedicines.